Outcome and clinical management of 275 patients with advanced ovarian cancer international federation of obstetrics and gynecology ii to iv inside the european ovarian cancer translational research consortium-ovcad

International Journal of Gynecological Cancer

Volumn 23, Issue 2, 2013, Pages 268-275

  Chekerov, Radoslav ^a   Braicu, Ioana ^a   Castillo Tong, Dan Cacsire ^b,c   Richter, Rolf ^a   Cadron, Isabelle ^d   Mahner, Sven ^e   Woelber, Linn ^e   Marth, Christian ^f   Van Gorp, Toon ^d,g   Speiser, Paul ^b   Zeillinger, Robert ^b,c   Vergote, Ignace ^d   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cytoreductive surgery; Ovarian cancer; Systemic treatment; Translational research

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ENZASTAURIN; ERLOTINIB; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SMALL INTESTINE RESECTION; TRANSLATIONAL RESEARCH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; EUROPE; FEMALE; GYNECOLOGY; HUMANS; INTERNATIONAL AGENCIES; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBSTETRICS; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; SOCIETIES, MEDICAL; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876209412     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31827de6b9     Document Type: Article

References (30)

1. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284-5293.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781.
3. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:23-30.
4. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: The state of the art. Int J Gynecol Cancer. 2005;15:212-220.
5. Vermorken JB. Second-line randomized trials in epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:59-66.
6. Sehouli J, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26:3176-3182.
7. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006;118:1963-1971.
8. Sehouli J, Konsgen D, Nimpsch R, et al. Detection of epithelial carcinoma cells in the blood of patients with gynaecological malignancies. Anticancer Res. 2003;23:1093-1097.
9. Hamilton TC, Connolly DC, Nikitin AY, et al. Translational research in ovarian cancer: A must. Int J Gynecol Cancer. 2003;13:220-230.
10. Zeillinger R, Castillo-Tong DC. OVCADV"Ovarian Cancer: Diagnosis of a silent killer". A Sixth Framework Programme (FP6) Project of the European Research Area 2005; Available at: Http://www.ovcad.eu/2005.
11. Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark. 2011;9:531-549.
12. Sehouli J, Konsgen D, Mustea A, et al. "IMO"Vintraoperative mapping of ovarian cancer [article in German]. Zentralbl Gynakol. 2003;125:129-135.
13. ChenVW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631-2642.
14. Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol. 1982;59:576-582.
15. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
16. Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117:429-439.
17. Lehmann F, Lacombe D, Therasse P, et al. Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms. J Transl Med. 2003;1:2.
18. Vergote I, Amant F. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Gynecol Oncol. 2006;102:415-417.
19. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.
20. Sehouli J, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656-662.
21. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234-1244.
22. Du Bois A, Rochon J, Lamparter C, et al. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183-191.
23. Harter P, Hilpert F, Mahner S, et al. Prognostic factors for complete debulking in first-and second-line ovarian cancer. Int J Gynecol Cancer. 2009;19:14-17.
24. Vergote I, Trope CJ, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
25. Verleye L, Vergote I, van der Zee AG. Patterns of care in surgery for ovarian cancer in Europe. Eur J Surg Oncol. 2010;36:108-114.
26. Aust S, Bachmayr-Heyda A, Tong D, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancerVa study of the OVCAD consortium. Mol Cancer. 2012;11:69.
27. Marme F, et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer. 2012;131:586-591.
28. Obermayr E, Castillo-Tong DC, Pils D, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significanceVa study of the OVCAD consortium. Gynecol Oncol. 2012;128:15-21.
29. Pils D, Hager D, Tong D, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. Cancer Sci. 2012;22:380-5.
30. Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: Analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22:380-385.